Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791855 · ClinicalTrials.gov registry record · Phase 1
PF-04634817 Renal Impairment Study
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01791855 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 32 participants.
The verdict
NCT01791855, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment. This study will investigate the effect of the drug in subjects with varying degrees of renal impairment. Pharmacokinetics, safety and toleration will be assessed.
Interventions
- DRUG PF-04634817
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-05-10 |
| Est. Completion | 2013-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01791855
The ClinicalTrials.gov registry entry for NCT01791855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04634817 is the first listed.
NCT01791855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01791855 about?
NCT01791855 is a clinical study titled "PF-04634817 Renal Impairment Study". Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment. This study will investigate the effect of the drug in subjects with varying degrees of renal impairment. Pharmacokine...
What is the current status of trial NCT01791855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-05-10. Estimated completion is 2013-09-03.
What interventions are being tested in trial NCT01791855?
The interventions under investigation include: PF-04634817 (DRUG).
Who is sponsoring clinical trial NCT01791855?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.